Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2015', provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Secondary Progressive Multiple Sclerosis (SPMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Secondary Progressive Multiple Sclerosis (SPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Secondary Progressive Multiple Sclerosis (SPMS) Overview 7 Therapeutics Development 8 Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Overview 8 Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Comparative Analysis 9 Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics under Development by Companies 10 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Secondary Progressive Multiple Sclerosis (SPMS) - Products under Development by Companies 15 Secondary Progressive Multiple Sclerosis (SPMS) - Companies Involved in Therapeutics Development 16 AB Science 16 Biogen Idec Inc. 17 Daval International Ltd. 18 Genzyme Corporation 19 Glialogix, Inc. 20 Immune Response BioPharma, Inc. 21 Innate Therapeutics Limited 22 Kyorin Pharmaceutical Co., Ltd. 23 MedDay 24 Novartis AG 25 Opexa Therapeutics, Inc. 26 Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 Aimspro - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 BIIB-033 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 DC-TAB - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 GLX-1112 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 GZ-402668 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ibudilast - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 imilecleucel-t - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 interferon beta-1b - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 IR-902 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 masitinib - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 MD-1003 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 MIS-416 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 natalizumab - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 siponimod - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Small Molecules for Multiple Sclerosis - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Secondary Progressive Multiple Sclerosis (SPMS) - Recent Pipeline Updates 61 Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products 78 Secondary Progressive Multiple Sclerosis (SPMS) - Product Development Milestones 79 Featured News & Press Releases 79 Oct 07, 2014: Update on Innate's Phase 2B trial and other recent activities 79 Aug 19, 2014: Innate's Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval 79 Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis 80 Jun 18, 2014: Compassionate Use Programme Update 80 May 13, 2014: Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis 81 Apr 15, 2014: Innate Immunotherapeutics confirms Phase 2B trial on track and on budget 82 Mar 11, 2014: Innate Immunotherapeutics receives EU patent protection for use of MIS416 to treat or prevent radiation injury 83 Feb 03, 2014: Dr Larry Steinman, renowned multiple sclerosis specialist at Stanford University, endorses newly published MIS416 therapy validation in animal studies 83 Dec 16, 2013: Opexa Therapeutics Provides MS Trial Enrollment Update; 70% of Patients Enrolled 84 Nov 13, 2012: Opexa Receives Clinical Trial Approval From Health Canada For New T-Cell Therapy, Tcelna 85 Appendix 86 Methodology 86 Coverage 86 Secondary Research 86 Primary Research 86 Expert Panel Validation 86 Contact Us 87 Disclaimer 87
List of Tables Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H1 2015 8 Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS) - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 11 Comparative Analysis by Late Stage Development, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by AB Science, H1 2015 16 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Biogen Idec Inc., H1 2015 17 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Daval International Ltd., H1 2015 18 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Genzyme Corporation, H1 2015 19 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Glialogix, Inc., H1 2015 20 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Immune Response BioPharma, Inc., H1 2015 21 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Innate Therapeutics Limited, H1 2015 22 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 23 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedDay, H1 2015 24 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Novartis AG, H1 2015 25 Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Opexa Therapeutics, Inc., H1 2015 26 Assessment by Monotherapy Products, H1 2015 27 Number of Products by Stage and Target, H1 2015 29 Number of Products by Stage and Mechanism of Action, H1 2015 31 Number of Products by Stage and Route of Administration, H1 2015 33 Number of Products by Stage and Molecule Type, H1 2015 35 Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics - Recent Pipeline Updates, H1 2015 61 Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products, H1 2015 78
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.